Download in electronic PDF format for $65

Abstract:  Pergolide mesylate (proprietary name Permax) is used to treat equine Cushing’s syndrome. Since pergolide mesylate has been removed from the market, the tablets are no longer available. Therefore, pergolide mesylate preparations have to be compounded for veterinary use. Compounded oral liquid formulations have been given arbitrary beyond-use dates of 14 days (aqueous) to 90 days (oil based). The goal of this study was to determine the stability of a 0.2 mg/mL pergolide oral liquid prepared according to a previously published formulation and stored at room temperature. The sample preparation and the high-performance liquid chromatographic assay described in the United States Pharmacopeia–National Formulary were modified to treat the oral liquid as a suspension. The assay was evaluated prior to its use. A linear relationship was found between peak area and concentration, with R2 values ranging from 0.989 to 0.999 for three of the sample calibration plots. The daily reproducibility and day-to-day variability of s

Related Keywords: Brandon R. Shank, Clyde M. Ofner III, BS, PhD, RPh, pergolide mesylate, stability, storage temperature, equine Cushing syndrome, horses, formulation

Related Categories: FORMULATIONS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, VETERINARY, DOSAGE FORMS/DRUG CARRIERS, STORAGE

Printer-Friendly Version